The study was aimed to evaluation the effect of different
magnesium salts and their combinations with
pyridoxine on a course of
calcium-oxalate nephrolithiasis, which was modeled by adding the
sodium oxalate (3% of weight of the diet) and selective
cyclooxygenase-2 inhibitor celecoxib at a dose 100 mg/kg
body weight to a diet for 4 weeks. Starting from the 2nd week of the experiment, the animals had received one of the following
compounds: magnesium L-aspartate,
magnesium chloride, and their combination with
vitamin B6;
magnesium sulfate and
Magne B6 (
magnesium lactate and
vitamin B6) as comparators. 28 days after the start of the experiment, disorders progressed in the group receiving only
celecoxib and
oxalate-rich diet: the urine level of
oxalate increased by 171% (p < 0,0001),
crystalluria had increased (up to 105 crystals in 10 microml of urinary sediment, p < 0,0001),
creatinine clearance decreased by 29%, compared to control (p = 0,087). Increasing
calcium/
magnesium and
oxalate/
creatinine ratios in urine by 16 and 189%, respectively, was observed. In the renal parenchyma of animals treated with
sodium oxalate and
celebrex, calcifications with a volume fraction of 4% were identified, whereas these changes were absent in intact animals. According to the degree of correction ofhyperoxaluria and elimination of
calcium oxalate crystals, investigated
salts showed similar efficacy, with the exception of
magnesium sulfate, which less contributed the compensation of abnormalities in kidney and urinary. According to the data of morphological study, the volume fraction of calcifications was lowest in the groups receiving
magnesium L-aspartate and
Magne B6.